MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
QUICK SEARCH:   [advanced]


     

Molecular Pharmacology Fast Forward
First published on October 19, 2007; DOI: 10.1124/mol.107.041764

This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
mol.107.041764v1
73/1/260    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Krynetskaia, N.
Right arrow Articles by Krynetskiy, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krynetskaia, N.
Right arrow Articles by Krynetskiy, E.


Received for publication September 12, 2007.
Revised October 19, 2007.
Accepted for publication October 19, 2007.

High mobility group protein B1 is an activator of apoptotic response to antimetabolite drugs

Natalia Krynetskaia 1, Hongbo Xie 1, Slobodan Vucetic 1, Zoran Obradovic 1, Evgeny Krynetskiy 2*

1 Temple University 2 Temple University School of Pharmacy

* Address correspondence to: E-mail: ekrynets{at}temple.edu

Abstract

We explored the role of a chromatin-associated nuclear protein HMGB1 in apoptotic response to widely used anticancer drugs. A murine fibroblast model system generated from Hmgb1+/+ and Hmgb1-/- mice was used to assess the role of HMGB1 protein in cellular response to anticancer nucleoside analogs and precursors which act without destroying integrity of DNA. Chemosensitivity experiments with 5-fluorouracil (FU), cytosine arabinoside (araC), and mercaptopurine (MP) demonstrated that Hmgb1-/- MEFs were 3-10 times more resistant to these drugs compared with Hmgb1+/+ MEFs. Hmgb1-deficient cells showed compromised cell cycle arrest and reduced caspase activation after treatment with MP and araC. Phosphorylation of p53 at Ser12 (corresponding to Ser 9 in human p53) and Ser18 (corresponding to Ser 15 in human p53), as well as phosphorylation of H2AX after drug treatment was reduced in Hmgb1-deficient cells. Trans-activation experiments demonstrated diminished activation of pro-apoptotic promoters Bax, Puma, and Noxa in Hmgb1-deficient cells after treatment with MP or araC, consistent with reduced transcriptional activity of p53. For the first time, we demonstrated that Hmgb1 is an essential activator of cellular response to genotoxic stress caused by chemotherapeutic agents (thiopurines, cytarabine and 5-fluorouracil), which acts at early steps of antimetabolite-induced stress by stimulating phosphorylation of two DNA damage markers p53 and H2AX. This finding makes HMGB1 a potential target for modulating activity of chemotherapeutic antimetabolites. Identification of proteins sensitive to DNA lesions which occur without the loss of DNA integrity provides new insights into the determinants of drug sensitivity in cancer cells.


Key words: DNA damage and repair, Mechanisms of cell killing/apoptosis, Nucleoside/Nucleotide derivatives, Resistance




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics